The potential therapeutic applications of RNAi were realized
almost immediately after the phenomenon was first described; over the years,
developers have gradually progressed their proprietary drug candidates with
cautious optimism
Roots Analysis is pleased to announce the publication of its recent
study, titled, “RNAi
Therapeutics Market (2nd Edition), 2019-2030.”
The “RNAi Therapeutics Market (2nd Edition), 2019-2030:
Focus On siRNA, miRNA, shRNA and DNA” report features an extensive study of the
current market landscape and future opportunities associated with RNAi
therapeutics. The study also features a detailed analysis of key drivers and
trends within this evolving market. Amongst other elements, the report includes:
§
A detailed assessment of the current market landscape of drug
developers engaged in the development of RNAi therapeutics.
§
A competitiveness analysis of key players engaged in this
domain, evaluating their respective product portfolios, type of RNAi molecule,
target therapeutic areas, company size and year of establishment
§
A detailed analysis of more than 70 completed, ongoing and
planned clinical studies of RNAi therapeutics.
§
A detailed analysis of various patents that have been filed
/ granted related to RNAi therapeutics, since 2014
§
An analysis of the partnerships that have been established
in this domain, in the recent past.
§
An analysis of the investments made at various stages of
development in companies engaged in this domain.
§
An analysis of the key promotional strategies that have
been adopted by developers of marketed oligonucleotide therapeutics, namely
Defitelio®, Exondys® and Onpattro®.
§
Detailed profiles of RNAi Therapeutics that are in the late
stage clinical development
§
A detailed market forecast, featuring analysis of the
current and projected future opportunity across key market segments (listed
below)
§
Oncological disorders
§
Infectious diseases
§
Genetic disorders
§
Ophthalmic disorders
§
Hepatic disorders
§
Respiratory disorders
§
siRNA
§
miRNA
§
shRNA
§
sshRNA
§
DNA
§
Subcutaneous
§
Intravenous
§
Intradermal
§
Intravitreal
§
Oral
§
Intramuscular
§
North America
§
Europe
§
Asia Pacific and the Rest of the world
Key
companies covered in the report
§
Quark Pharmaceuticals
§
Alnylam Pharmaceuticals
§
Dicerna Pharmaceuticals
§
Souzhou Ribo Life Sciences
§
Olix Pharmaceuticals
§
Sirnaomics
§
Ariz Precision Medicine
§
Arrowhead Pharmaceuticals
§
Gradalis
§
Benitec Biopharma
For
more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Other Recent Offerings
1.
Gene Therapy Market (3rd
Edition), 2019-2030
2.
Global T-Cell (CAR-T,
TCR and TIL) Therapy Market (4th Edition), 2019-2030
3.
Biopharma Contract
Manufacturing Market
(3rd Edition), 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market
research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
